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Lysosomal Storage Disorders (LSDs) are a group of rare inherited diseases caused by the 
malfunction of the lysosomal system, resulting in the accumulation of undegraded substrates 
inside the lysosomes and leading to severe and progressive pathology. Among them is 
Mucolipidosis II (ML II), one of most severe LSDs, which is caused by the total or near total 
deficiency of the GlcNAc-phosphotransferase, a key enzyme for the correct trafficking of 
lysosomal hydrolases to the lysosome. GlcNAc-phosphotransferase is a multimeric enzyme 
and is encoded by two genes: GNPTAB and GNPTG. One of the most frequent ML II causal 
mutations is a dinucleotide deletion on exon 19 of the GNPTAB gene that disrupts the reading 
frame and prevents the production of an active GlcNAc-phosphotransferase, which in turn 
impairs the proper targeting of lysosomal enzymes. Despite broad understanding of the 
molecular causes behind this and other LSDs, the same progress has not been observed in the 
development of new therapies, with current treatments still mostly symptomatic and 
presenting several limitations. Therefore, alternative options should be investigated in order 
to provide patients and families with better healthcare and more promising therapies. One 
possibility is the modulation of splicing by antisense oligonucleotides (AOs) with the purpose 
of altering the splicing pattern, the mature mRNA and ultimately the final protein product. 
Acknowledging this, the present study intends to design and develop a RNA-based 
therapeutic agent through the use of AOs capable of inducing the skipping of exon 19 of the 
GNPTAB gene and consequently circumvent the effects of the most common ML II causal 
mutation. The approach is presently ongoing and different 2’O-Methyl AOs were designed 
and synthesized to target the GNPTAB exon 19 and promote its skipping. We have already 
succeeded in inducing the skipping of exon 19 in control and ML II patient fibroblasts. At 
biochemical level, 48 hours following transfection, enzyme activity suffered a small increase 
in patients fibroblasts for all enzymes tested, even if the results are still much lower than the 
observed for healthy controls. In conclusion, this work constitutes a proof of principle for 
correcting in vitro the defects caused by a frequent ML II mutation with antisense therapy.  
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